Genzyme Arthritis Treament Approval Delayed

Genzyme (NASDAQ: GENZ) announced today that approval of its knee osteoarthritis treatment Synvisc-One will be delayed until the second half of next year, or later, because the FDA has requested more data on the treatment. Synvisc-One combines three doses of an already approved treatment, Synvisc, into a single injection.

The news marks a second recent disappointment for Cambridge, MA-based Genzyme’s osteoarthritis program: in July another of its treatments, called hylastan, failed to meet efficacy targets in clinical trials. At the time, the company said it was abandoning development of hylastan to focus on Synvisc-One.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

One response to “Genzyme Arthritis Treament Approval Delayed”

  1. 8 Tips for Arthritis Tip 1: Make Sure You Really Have Osteoarthritis While to some of you, today’s tip might be very basic. It is absolutely essential that you make sure your diagnosis is correct before you begin wasting money on treatments that are not designed to help your specific situation. Tip 2: Searching For Just Arthritis Pain Relief? You Shouldn’t! Doctors are very quick to address your joint pain with what has become a “standard” response. Normally, they tell you to take NSAIDS like Aspirin, Advil, Motrin, Ibuprofen, and Acetaminophen, or prescribe COX-2 inhibitors such as Vioxx and Celebrex.